NCT06687837View on ClinicalTrials.gov

Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons

PHASE1RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Parkinson Disease
Interventions
BIOLOGICAL

autologous dopaminergic cell implantation

Dopaminergic progenitor cells derived from autologous induced pluripotent stem cells will be injected into the brain in two cohorts of Parkinson's patients, one receiving low dose and the other high dose (4 and 8 million cells, respectively)

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Jeffrey S. Schweitzer, MD, PhD

OTHER